Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T18:21:13.224Z Has data issue: false hasContentIssue false

The effects of guar gum supplementation on lipid profile in adults: a GRADE-assessed systematic review, meta-regression and dose–response meta-analysis of randomised placebo-controlled trials

Published online by Cambridge University Press:  15 July 2022

Leila Setayesh
Affiliation:
Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA
Sanaz Pourreza
Affiliation:
Department of Clinical Nutrition, School of Nutritional Science, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Zeinali Khosroshahi
Affiliation:
Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
Omid Asbaghi
Affiliation:
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Reza Bagheri*
Affiliation:
Department of Exercise Physiology, University of Isfahan, Isfahan, Iran
Mahnaz Rezaei Kelishadi
Affiliation:
Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
Alexei Wong
Affiliation:
Department of Health and Human Performance, Marymount University, Arlington, USA
Cain C.T. Clark
Affiliation:
Centre for Intelligent Healthcare, Coventry University, Coventry CV1 5FB, UK
Damoon Ashtary Larky
Affiliation:
Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Katsuhiko Suzuki
Affiliation:
Faculty of Sport Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa 359-1192, Japan
Matin Ghanavati*
Affiliation:
Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*
* Corresponding authors: Reza Bagheri, email [email protected]; Matin Ghanavati, email [email protected]
* Corresponding authors: Reza Bagheri, email [email protected]; Matin Ghanavati, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Recent meta-analytic work indicated that guar gum supplementation might improve lipid profile markers in different populations. However, critical methodological limitations such as the use of some unreliable data and the lack of inclusion of several relevant studies, and the scarcity in assessments of regression and dose-specific effects make it difficult to draw meaningful conclusions from the meta-analysis. Therefore, current evidence regarding the effects of guar gum supplementation on lipid profile remains unclear. The present systematic review, meta-regression and dose–response meta-analysis aimed to examine the effects of guar gum supplementation on lipid profile (total cholesterol (TC), LDL, TAG and HDL) in adults. Relevant studies were obtained by searching the PubMed, SCOPUS, Embase and Web of Science databases (from inception to September 2021). Weighted mean differences (WMD) and 95 % CI were estimated via a random-effects model. Heterogeneity, sensitivity analysis and publication bias were reported using standard methods. Pooled analysis of nineteen randomised controlled trials (RCT) revealed that guar gum supplementation led to significant reductions in TC (WMD: −19·34 mg/dl, 95 % CI −26·18, −12·49, P < 0·001) and LDL (WMD: −16·19 mg/dl, 95 % CI −25·54, −6·83, P = 0·001). However, there was no effect on TAG and HDL among adults in comparison with control group. Our outcomes suggest that guar gum supplementation lowers TC and LDL in adults. Future large RCT on various populations are needed to show further beneficial effects of guar gum supplementation on lipid profile and establish guidelines for clinical practice.

Type
Systematic Review and Meta-Analysis
Copyright
© University, 2022. Published by Cambridge University Press on behalf of The Nutrition Society

Dyslipidaemia is generally due to abnormal lipid metabolism, which results in increased concentrations of total cholesterol (TC), LDL, TAG and/or reduced HDL(Reference Mancini, Hegele and Leiter1). Clinical studies also suggest that this condition elevates the risk of CVD mortality by facilitating the onset and progression of atherosclerosis(Reference Peng, Luo and Ruan2). In fact, prolonged exposure to even moderately elevated cholesterol concentrations is known to increase the risk of CVD later in life(Reference Ashtary-Larky, Bagheri and Ghanavati3Reference Asbaghi, Choghakhori and Ashtary-Larky5). Therefore, identifying effective interventions for the improvement of lipid profile is an important public health concern.

There are several approaches for controlling dyslipidaemia, including safe and secure methods such as dietary interventions, and unlike pharmacological therapies, they do not cause any long-term side effects(Reference Kelly6Reference Asbaghi, Fouladvand and Moradi9). Interventions that improve dietary soluble fibre intake, in particular, have received considerable interest due to their hypolipidaemic effects and effectiveness in reducing the prescribed dose of statins(Reference Surampudi, Enkhmaa and Anuurad10Reference Ballesteros, Cabrera and Saucedo13).

Guar gum is a rich source of soluble fibre(Reference Yoon, Chu and Juneja14) and is derived from the seeds of the Cyamopsis tetragonoloba plant(Reference Whistler and Hymowitz15). Numerous clinical trials have examined the effects of guar gum supplementation on various diseases, such as diabetes, irritable bowel syndrome and dyslipidaemia(Reference Aro, Uusitupa and Voutilainen16Reference Groop, Aro and Stenman19). Animal studies suggest that guar gum supplementation has hypolipidaemic effects(Reference Saeed, Mosa-Al-Reza and Fatemeh20Reference Frias and Sgarbieri22). While numerous human studies have been performed to investigate the effects of guar gum supplementation on lipid profile, results have been contradictory. Indeed, some studies have shown that guar gum supplementation effectively improves lipid profile(Reference Aro, Uusitupa and Voutilainen16,Reference Groop, Aro and Stenman19,Reference Khan, Khan and Mitchel23) , while others do not show such an effect(Reference Tuomilehto, Voutilainen and Huttunen24,Reference Makkonen, Simpanen and Saarikoski25) . Recently, a meta-analysis has been published on the topic by Wang et al. (Reference Wang, Pan and Guo26), which revealed that guar gum supplementation significantly decreased serum concentrations of LDL and TC but did not affect TAG and HDL. However, two critical limitations make it difficult to draw meaningful conclusions from their investigation. The first is the failure to incorporate six relevant studies on the topic(Reference Dall’Alba, Silva and Antonio18,Reference Groop, Aro and Stenman19,Reference Farrell, Owens and Tomkin27Reference Ebeling, Yki-Järvinen and Aro30) that meet the inclusion criteria set forth by Wang et al. (Reference Wang, Pan and Guo26). The second limitation is that four studies without a placebo/control group were incorporated in the analysis(Reference Cicero, Derosa and Manca31Reference Vaaler, Hanssen and Dahl-Jørgensen34), and therefore their outcomes may not account for some unspecific effects of observation and expectation (i.e. the Hawthorne and placebo effects). Consequently, the overall effects of guar gum supplementation on lipid profile remain unclear. Thus, we sought to conduct a systematic review, meta-regression and dose–response meta-analysis of randomised placebo-controlled trials (RCT) to quantitatively assess the effects of guar gum supplementation on lipid profile markers in adults based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines(Reference Stroup, Berlin and Morton35).

Experimental methods

Search strategy

We searched PubMed, Embase, Scopus and Web of Science databases from inception through September 2021, by using the following terms: Guar OR Guaran, which was paired with the following words: Intervention OR ‘Intervention Study’ OR ‘Intervention Studies’ OR ‘controlled trial’ OR randomised OR random OR randomly OR placebo OR ‘clinical trial’ OR Trial OR ‘randomized controlled trial’ OR ‘randomized clinical trial’ OR RCT OR blinded OR ‘double blind’ OR ‘double blinded’ OR trial OR ‘clinical trial’ OR trials OR ‘Pragmatic Clinical Trial’ OR ‘Cross-Over Studies’ OR ‘Cross-Over’ OR ‘Cross-Over Study’ OR parallel OR ‘parallel study’ OR ‘parallel trial’. There were no date and language restrictions included in each of the database searches. Additional studies not captured by our database search were retrieved via a manual search of references from the originally identified reviews and research reports.

Study selection and eligibility criteria

Two authors (MZ and OA) reviewed the titles, abstracts, references and full texts of relevant articles to select eligible studies. The inclusion criteria were as follows: (1) adult participants who had supplemented with guar gum for ≥ 2 weeks; (2) the studies had a control group where the only difference between the treatment and control groups was the supplementation of guar gum; (3) the trial reported effects on TC, TAG, LDL or HDL; (4) the use of an RCT design; and (5) guar gum not being administered as part of a multicomponent supplement in either the experimental or control group. The exclusion criteria were as follows: (1) trials that enrolled children or pregnant women; (2) not focusing on our outcomes; and (3) animal, review, conference and case-report studies.

Risk of bias

The quality of eligible studies was assessed using the Cochrane risk of bias tool for RCT(Reference Higgins, Altman and Gotzsche36). Two independent investigators (TM and MDM) completed this checklist for each included paper. Methodological features applied for assessment were as follows: (1) adequate sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective outcome reporting (reporting bias) and (7) other potential sources of bias. Based on the mentioned items, studies were classified in terms of bias into three groups: low risk, moderate risk and high risk of bias(Reference Higgins, Altman and Gotzsche36).

Data extraction

The following data were extracted from included studies by two authors (MZ and OA) independently: study characteristics (the first author, country, year of publication, study design, sample size in each group, study duration, intervention type and dose), participant characteristics (mean age, sex and BMI), as well as the mean and standard deviation of TC, LDL, HDL and TAG concentrations in pre-intervention and post-intervention. In this study, all values were converted to a milligram per decilitres (mg/dl).

Statistical analysis

We performed this meta-analysis using STATA statistical software (version 14; STATA Corp LP). Treatment effects were defined as the weighted mean differences (WMD) and 95 % CI and were determined using the random-effects model, following the DerSimonian and Laird method(Reference DerSimonian and Laird37). We calculated changes in TC, LDL, HDL and TAG concentrations between the intervention and control groups from baseline to the end of the intervention period, and the following formula was used to calculate sd change from sd baseline and final: sd 2 baseline + sd 2 final – (2 × R × sd baseline × sd final)(Reference Borenstein, Hedges and Higgins38). Pre-specified subgroup analyses were performed according to baseline serum lipid profile (TAG, TC, LDL and HDL), guar dosage (≤ 15 g/d v. > 15 g/d), duration of the intervention (≥ 12 weeks v. < 12 weeks) and diabetes status of participants (diabetic v. non-diabetic participants). Sensitivity analyses were performed to assess the stability of the results by removing one study at a time to identify the impact of individual studies on the pooled effect size. Funnel plots and Egger’s regression test were used to assess the publication bias. A P-value of < 0·05 was considered statistically significant in this trial unless otherwise specified(Reference Egger, Smith and Schneider39). The potential non-linear effects of guar dose (g/d) and intervention duration (weeks) were investigated using fractional polynomial modelling. Also, we enforced the meta-regression to differentiate the confounders and linear relations among the effect size and sample size, duration and intervention dosage(Reference Mitchell40).

Certainty assessment

The overall certainty of evidence across the studies was graded according to the GRADE guidelines (Grading of Recommendations Assessment, Development and Evaluation) Working Group. According to the corresponding evaluation criteria, the quality of evidence was classified into four categories: high, moderate, low and very low(Reference Gordon, Oxman and Vist41).

Results

Study selection

In the primary search, we detected a total of 1940 records, where 823 duplicates were identified and removed. After screening based on title and abstract, twenty-six articles were retained for further evaluation. Three articles were excluded because they did not report lipid profiles. Also, four other studies were excluded from the study because they did not have a control group. Subsequently, nineteen eligible studies were included in qualitative and quantitative synthesis (meta-analysis)(Reference Dall’Alba, Silva and Antonio18,Reference Groop, Aro and Stenman19,Reference Khan, Khan and Mitchel23Reference Makkonen, Simpanen and Saarikoski25,Reference Peterson, Ellis and Baylis28Reference Ebeling, Yki-Järvinen and Aro30,Reference Aro, Uusitupa and Voutilainen42Reference Vuorinen-Markkola, Sinisalo and Koivisto51) (Fig. 1).

Fig. 1. Flow chart of study selection for inclusion trials in the systematic review.

Characteristics of the included studies

The general characteristics of the included studies are outlined in online Supplementary Table 1. The studies were published between 1980 and 2013 and were carried out in Finland(Reference Tuomilehto, Voutilainen and Huttunen24,Reference Makkonen, Simpanen and Saarikoski25,Reference Ebeling, Yki-Järvinen and Aro30,Reference Aro, Uusitupa and Voutilainen42,Reference Aro, Uusitupa and Voutilainen43,Reference Uusitupa, Siitonen and Savolainen47,Reference Tuomilehto, Silvasti and Aro49,Reference Vuorinen-Markkola, Sinisalo and Koivisto51,Reference Groop, Aro and Stenman52) , USA(Reference Khan, Khan and Mitchel23,Reference McIvor, Cummings and Van Duyn44,Reference Superko, Haskell and Sawrey-Kubicek48) , UK(Reference Peterson, Ellis and Baylis28,Reference Blake, Hamblett and Frost29,Reference Fuessl, Williams and Adrian45,Reference Lalor, Bhatnagar and Winocour50) , Ireland(Reference Farrell, Owens and Tomkin46), Brazil(Reference Dall’Alba, Silva and Antonio18) and Saudi Arabia(Reference Laajam, Jim and El-Bolbol53). The follow-up period ranged from 3 to 26 weeks, while the daily recommended dosage of guar gum varied between 8·3 and 39 g. All studies were conducted using both sexes, except for two trials performed exclusively on women(Reference Tuomilehto, Voutilainen and Huttunen24,Reference Makkonen, Simpanen and Saarikoski25) and two on men(Reference Aro, Uusitupa and Voutilainen43,Reference Superko, Haskell and Sawrey-Kubicek48) . The sample size in the included trials ranged from 14 to 58. Overall, 525 participants were amalgamated in these studies, of which 268 individuals were allocated to guar gum supplementation and 257 participants to the placebo group. The mean age of the participants ranged from 25 to 61·3 years old and included patients with hypercholesterolemia(Reference Tuomilehto, Voutilainen and Huttunen24,Reference Blake, Hamblett and Frost29,Reference Aro, Uusitupa and Voutilainen43,Reference Tuomilehto, Silvasti and Aro49,Reference Vuorinen-Markkola, Sinisalo and Koivisto51) , type 2 diabetes(Reference Dall’Alba, Silva and Antonio18,Reference Groop, Aro and Stenman19,Reference Peterson, Ellis and Baylis28,Reference Aro, Uusitupa and Voutilainen42,Reference McIvor, Cummings and Van Duyn44Reference Uusitupa, Siitonen and Savolainen47,Reference Lalor, Bhatnagar and Winocour50) , type 1 diabetes(Reference Ebeling, Yki-Järvinen and Aro30), menopausal women(Reference Makkonen, Simpanen and Saarikoski25) and healthy participants(Reference Khan, Khan and Mitchel23,Reference Superko, Haskell and Sawrey-Kubicek48) (online Supplementary Table 1).

Effect of guar gum supplementation on TAG concentrations

Sixteen studies, including a total of 477 participants (case = 283 and control = 272), reported TAG as an outcome measure. Overall results from the random-effects model suggested that guar gum supplementation resulted in a non-significant decrease in TAG concentrations (WMD: −2·80 mg/dl, 95 % CI −10·05, 2·45, P = 0·233) (Fig. 2(a)). Heterogeneity was not observed between studies. Also, subgroup analysis demonstrated the same results (online Supplementary Table 3).

Fig. 2. Forest plot detailing weighted mean difference and 95 % CI for the effect of guar gum supplementation on: (a) TAG; (b) TC; (c) LDL-cholesterol and (d) HDL-cholesterol.

Effect of guar gum supplementation on total cholesterol concentrations

Pooling effect sizes from seventeen publications, including 499 participants (case = 289 and control = 288), we found that guar gum supplementation had a significant effect on TC concentrations compared with placebo (WMD: −19·34 mg/dl, 95 % CI −26·18, −12·49, P < 0·001), with considerable between-study heterogeneity (I2 = 69·4 %, P < 0·001) (Fig. 2(b)). Subgroup analysis based on guar gum dosage, baseline TC concentrations, trial duration and diabetes status revealed that these factors explained the heterogeneity. In addition, diabetes status is known as a source of heterogeneity (online Supplementary Table 3).

Effect of guar gum supplementation on LDL concentrations

The influence of guar gum supplementation on LDL concentrations was evaluated in twelve trials, including 369 participants (case = 190 and control = 179). The pooled estimates highlighted that in participants who supplemented with guar gum, LDL concentrations were significantly decreased compared with placebo (WMD: −16·19 mg/dl, 95 % CI −25·54, −6·83, P = 0·001). There was a significant between-study heterogeneity (I2 = 76·2 %, P < 0·001) (Fig. 2(c)). Subgroup analysis revealed that baseline LDL concentrations and diabetes status were sources of heterogeneity. In addition, the results remained significant when baseline LDL ≥ 130 mg/dl, trial duration < 12 or ≥ 12 weeks, and intervention dose < 15 g/d and in non-diabetic participants (online Supplementary Table 3).

Effect of guar gum supplementation on HDL concentrations

Overall, fifteen eligible studies, including a total of 441 participants (case = 226 and control = 215), examined the effect of guar gum supplementation on HDL concentrations. Combining their findings based on a random-effects model, we found that HDL concentrations did not significantly change after intervention (WMD: −0·59 mg/dl, 95 % CI −1·92, 0·73, P = 0·382) compared with the control group, with no significant between-study heterogeneity (Fig. 2(d)). Subgroup analysis showed that guar gum supplementation significantly increased HDL concentrations only when baseline HDL concentrations were ≥ 50 mg/dl (online Supplementary Table 3).

Publication bias

Evaluation of publication bias by visual inspection of funnel plot revealed no evidence of publication bias in the meta-analysis of guar gum supplementation on TAG, TC, LDL and HDL concentrations, respectively (Fig. 3(a)–(d)).

Fig. 3. Funnel plot for the effect of guar gum supplementation on; (a) TAG; (b) TC; (c) LDL-cholesterol and (d) HDL-cholesterol.

Quality assessment

All studies were low risk for random sequence generation, except for one study that was unclear(Reference Groop, Aro and Stenman19). None of the studies reported allocation concealment, and three of the studies had high risk(Reference Dall’Alba, Silva and Antonio18,Reference Groop, Aro and Stenman19,Reference Groop, Groop and Tötterman54) . All studies had a high risk of bias for other sources of bias. All studies had a low risk of bias regarding selective reporting except for seven studies(Reference Groop, Aro and Stenman19,Reference Tuomilehto, Voutilainen and Huttunen24,Reference Makkonen, Simpanen and Saarikoski25,Reference Ebeling, Yki-Järvinen and Aro30,Reference Aro, Uusitupa and Voutilainen42,Reference Farrell, Owens and Tomkin46,Reference Uusitupa, Siitonen and Savolainen47) . Moreover, all studies had a low risk of bias regarding blinding participants and personnel, except for three studies(Reference Groop, Aro and Stenman19,Reference Peterson, Ellis and Baylis28,Reference Superko, Haskell and Sawrey-Kubicek48) . Four studies had a low risk of bias regarding blinding outcome assessors(Reference Dall’Alba, Silva and Antonio18,Reference Groop, Aro and Stenman19,Reference Blake, Hamblett and Frost29,Reference Superko, Haskell and Sawrey-Kubicek48) (online Supplementary Table 2).

Grading of evidence

The GRADE profile for the certainty of the evidence is included in online Supplementary Table 4. Both TAG and HDL were regarded as moderate quality due to serious limitations in indirectness and imprecision. The evidence relating to TC was moderate quality because of serious limitations in indirectness and inconsistency. Evidence regarding LDL was identified as low quality, owing to very serious limitations in inconsistency and serious limitations in indirectness.

Linear meta-regression and non-linear relationship between dose and duration of intervention and changes in lipid profile

There was no linear (Figs. 4 and 5) and non-linear (Figs. 6 and 7) relationship between changes in dose and duration of intervention and changes in lipid profile. However, there was a significant non-linear relationship between changes in dose of guar supplementation and alteration in HDL (coefficiency = 1·496 724, P = 0·044).

Fig. 4. Random-effects meta-regression plots of the association between dose of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Fig. 5. Random-effects meta-regression plots of the association between duration of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Fig. 6. Random-effects meta-regression plots of the association between dose of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Fig. 7. Random-effects meta-regression plots of the association between duration of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Discussion

The present systematic review and meta-analysis of RCT examined the effects of guar gum supplementation on lipid profile in adult populations. Our results showed that guar gum supplementation significantly reduces TC and LDL; however, there was no significant effect on TAG and HDL concentrations. Moreover, there was a significant non-linear relationship between changes in dose of guar supplementation and alteration in HDL concentrations.

In addition to pharmacological therapy for the treatment of dyslipidaemia, a primary focus of many researchers has been to establish efficacious and alternative treatments with lesser side effects. Indeed, many experimental and human studies have shown that guar gum supplementation exhibits hypocholesterolemic properties(Reference Trautwein, Kunath-Rau and Erbersdobler55). Accordingly, the present study indicated that guar gum supplementation significantly decreased TC and LDL concentrations. Concordant with our findings, a non-randomised clinical study demonstrated that daily guar gum supplementation for 3 months significantly decreased TC, with no effect on TAG concentrations(Reference Figueiredo, Alfenas and Franceschini56). In addition, in a double-blind crossover trial conducted by Niemi et al., 12 weeks of guar gum supplementation resulted in 10 % lower cholesterol, without any significant change in HDL or TAG concentrations(Reference Niemi, Keinänen-Kiukaanniemi and Salmela32). Further, Wirth et al. showed that, in patients with familial hypercholesterolemia, guar gum supplementation significantly reduced plasma TC and LDL concentrations after 3 months when administered concurrently with bezafibrate(Reference Wirth, Middelhoff and Braeuning57). Similarly, Tuomilehto et al. reported that a combination of gemfibrozil and guar gum supplementation significantly lowered TC and LDL concentrations and improved HDL:LDL ratio(Reference Tuomilehto, Silvasti and Manninen58). Clinically, declines of 39 mg/dl in TC and LDL concentrations can lessen all-cause mortality by 25 % and 16 % and CHD mortality by 25 % and 28 %, respectively(Reference Gould, Davies and Alemao59). Therefore, the results from our pooled analysis showing significant reductions in TC (–19·34 mg/dl) and LDL (–16·19 mg/dl) concentrations support the clinical significance of guar gum supplementation as a non-pharmacological strategy for lipid control.

Our study did not show any significant influence of guar gum supplementation on TAG and HDL concentrations. Indeed, findings from previous studies in this area align with our outcomes(Reference Aro, Uusitupa and Voutilainen16,Reference Knopp, Superko and Davidson60,Reference Krotkiewski61) . Bosello et al. showed that a 60-d intervention with guar gum supplementation decreased TC and led to plasma TAG concentrations reduction in patients suffering from familial combined hyperlipoproteinemia(Reference Bosello, Cominacini and Zocca62). A murine experimental study indicated that when rats were fed with a guar gum diet, a significant decrease in cholesterol and TAG concentrations along with higher HDL and HDL:LDL ratio was noted(Reference Frias and Sgarbieri22). In another study conducted by Gatti et al., guar gum supplementation yielded a reduction of TAG and TC concentrations when administered as guar-enriched pasta in diabetic and hyperlipidaemic patients(Reference Gatti, Catenazzo and Camisasca63). Dietary treatment in this study was so strict that the intake of ethanol and sucrose, with their known hypertriacylglycerolaemic effects, was excluded(Reference Gatti, Catenazzo and Camisasca63,Reference Burgeiro, Cerqueira and Varela-Rodríguez64) . Yamamoto et al. observed that a mixture of xanthan and guar gum supplementation had a hypertriacylglycerolaemic effect in diabetic rats, which might be due to high viscosity of intestinal content that resulted in delayed absorption of triacylglycerol(Reference Yamamoto, Sogawa and Nishina65). Moreover, Pasquier et al. hypothesised that high- and medium-viscous fibres could change the emulsification of dietary lipids and a subsequent reduction of TAG lipolysis in the duodenum(Reference Pasquier, Armand and Castelain66) as our subgroup analyses showed that guar gum supplementation, specifically in diabetic patients, decreased TAG concentrations. One possible explanation for this result is the use of antidiabetic drugs such as metformin, which has been reported to be accompanied by decreases in TAG(Reference Zhou, Massey and Story67). Another explanation for a tendency towards reducing TAG concentrations might be due to small but significant weight loss, as reported by Jenkins et al. (Reference Jenkins, Reynolds and Slavin68). Thus, further investigations are necessary to clarify the effect of guar gum supplementation on TAG concentrations.

The mechanisms through which soluble fibres, such as guar, might affect lipid profile are unclear. Studies suggest that when micelles are forming in the lumen, soluble fibres bind to bile acids or cholesterol, leading to decreased enterohepatic circulation(Reference Turner, Tuomilehto and Happonen69,Reference Brown, Rosner and Willett70) . Viscosity, a physicochemical property associated with dietary fibres (particularly soluble dietary fibres), also contributes to the physiological effects of dietary fibre via decreases in the diffusion of nutrients(Reference Dikeman and Fahey71). This is accomplished by reduced contact between food and digestive enzymes, altered contractile movements, slowed gastric emptying, and a thickening of the unstirred water layer through which glucose and cholesterol diffuse in the lumen(Reference Dikeman and Fahey71). Soluble fibres inhibit the reabsorption of bile acids from the intestine, and they might also interfere with cholesterol absorption(Reference Lalor, Bhatnagar and Winocour50). As the faecal loss of bile acids increases and the bile acid pool decreases, the liver produces more bile acids from cholesterol, lessening hepatic free cholesterol concentrations(Reference Rideout, Harding and Jones72). When cholesterol reduces, an up-regulation of LDL receptors occurs, leading to higher clearance of LDL(Reference Brown, Rosner and Willett70). Another suggested mechanism is the mediating effect of SCFA produced due to bacterial fermentation that contributes to the prevention of hepatic fatty acid synthesis(Reference Chen, Anderson and Jennings73).

Some limitations need to be considered when interpreting our results. Although guar gum was used in different dosages and forms, the impact of the various forms of guar gum was not examined. Further investigations are required to address questions specific to efficacy, compliance and side effects. In addition, the intervention period varied among the studies. Finally, except for one study, all the included studies were conducted among Western countries; therefore, examining the influences of guar gum supplementation in non-Western countries and other races is necessitated.

Conclusion

In conclusion, guar gum supplementation seems to favourably affect TC and LDL but without significant alterations in TAG and HDL concentrations. Given the limitations of the included studies, further investigations with various guar forms in different countries are needed to shed light on this issue.

Acknowledgements

Financial support: None.

Authorship: Conceptualization: [LS and SP]; Methodology: [OA, MRK, RB, and DAL]; Formal analysis and investigation: [OA]; Writing - original draft preparation: [LS, MZK, RB, SP, and OA]; Writing - review and editing: [AW, CCTC, DAL, RB, KS, and MG]; Supervision: [RB and MG].

The authors declare no conflict of interest.

Supplementary material

For supplementary material/s referred to in this article, please visit https://doi.org/10.1017/S0007114522002136

References

Mancini, GBJ, Hegele, RA & Leiter, LA (2018) Dyslipidemia. Can J Diabetes 42, S178S185.CrossRefGoogle ScholarPubMed
Peng, J, Luo, F, Ruan, G, et al. (2017) Hypertriglyceridemia and atherosclerosis. Lipid Health Dis 16, 233.CrossRefGoogle ScholarPubMed
Ashtary-Larky, D, Bagheri, R, Ghanavati, M, et al. (2021) Effects of Betaine Supplementation on Cardiovascular Markers: a Systematic Review and Meta-Analysis. Milton Park, Abingdon-on-Thames: Oxfordshire United Kingdom. pp. 118.Google ScholarPubMed
Dehbalaei, MG, Ashtary-Larky, D, Mesrkanlou, HA, et al. (2021) The effects of magnesium and vitamin E co-supplementation on some cardiovascular risk factors: a meta-analysis. Clin Nutr ESPEN 41, 110117.CrossRefGoogle ScholarPubMed
Asbaghi, O, Choghakhori, R, Ashtary-Larky, D, et al. (2020) Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. Clin Nutr ESPEN 37, 148156.CrossRefGoogle ScholarPubMed
Kelly, RB (2010) Diet and exercise in the management of hyperlipidemia. Am Fam Phys 81, 10971102.Google ScholarPubMed
Ruixing, Y, Jinzhen, W, Yaoheng, H, et al. (2008) Associations of diet and lifestyle with hyperlipidemia for middle-aged and elderly persons among the Guangxi Bai Ku Yao and Han populations. J Am Dietetic Assoc 108, 970976.CrossRefGoogle ScholarPubMed
Namkhah, Z, Ashtary-Larky, D, Naeini, F, et al. (2021) Does Vitamin C Supplementation Exert Profitable Effects on Serum Lipid Profile in Patients with Type 2 Diabetes? A Systematic Review and Dose-Response Meta-Analysis, Amsterdam, Netherlands. pp. 105665.Google ScholarPubMed
Asbaghi, O, Fouladvand, F, Moradi, S, et al. (2020) Effect of green tea extract on lipid profile in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Syndrome: Clin Res Rev 14, 293301.CrossRefGoogle ScholarPubMed
Surampudi, P, Enkhmaa, B, Anuurad, E, et al. (2016) Lipid lowering with soluble dietary fiber. Curr Atheroscler Rep 18, 75.CrossRefGoogle ScholarPubMed
Soliman, GA (2019) Dietary fiber, atherosclerosis, and cardiovascular disease. Nutrients 11, 1155.CrossRefGoogle ScholarPubMed
Ramos, SC, Fonseca, FA, Kasmas, SH, et al. (2011) The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutr J 10, 80.CrossRefGoogle ScholarPubMed
Ballesteros, MN, Cabrera, RM, Saucedo, MS, et al. (2001) Dietary fiber and lifestyle influence serum lipids in free living adult men. J Am Coll Nutr 20, 649655.CrossRefGoogle ScholarPubMed
Yoon, S-J, Chu, D-C & Juneja, LR (2008) Chemical and physical properties, safety and application of partially hydrolized guar gum as dietary fiber. J Clin Biochemistry Nutr 42, 17.CrossRefGoogle ScholarPubMed
Whistler, RL & Hymowitz, T (1979) Guar: Agronomy, Production, Industrial Use, and Nutrition. West Lafayette, Indiana: Purdue University Press.Google Scholar
Aro, A, Uusitupa, M, Voutilainen, E, et al. (1981) Improved diabetic control and hypocholesterolaemic effect induced by long-term dietary supplementation with guar gum in type 2 (insulin-independent) diabetes. Diabetologia 21, 2933.CrossRefGoogle ScholarPubMed
Niv, E, Halak, A, Tiommny, E, et al. (2016) Randomized clinical study: partially hydrolyzed guar gum (PHGG) v. placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab 13, 17.CrossRefGoogle Scholar
Dall’Alba, V, Silva, FM, Antonio, JP, et al. (2013) Improvement of the metabolic syndrome profile by soluble fibre – guar gum – in patients with type 2 diabetes: a randomised clinical trial. Br J Nutr 110, 16011610.CrossRefGoogle ScholarPubMed
Groop, P, Aro, A, Stenman, S, et al. (1993) Long-term effects of guar gum in subjects with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 58, 513518.CrossRefGoogle ScholarPubMed
Saeed, S, Mosa-Al-Reza, H, Fatemeh, AN, et al. (2012) Antihyperglycemic and antihyperlipidemic effects of guar gum on streptozotocin-induced diabetes in male rats. Pharmacogn Mag 8, 65.CrossRefGoogle Scholar
Mosa-Al-Reza, H, Sadat, DA & Marziyeh, A (2012) Comparison of the beneficial effects of guar gum on lipid profile in hyperlipidemic and normal rats. J Med Plants Res 6, 15671575.Google Scholar
Frias, AD & Sgarbieri, V (1998) Guar gum effects on food intake, blood serum lipids and glucose levels of Wistar rats. Plant Foods for Hum Nutr 53, 1528.CrossRefGoogle ScholarPubMed
Khan, AR, Khan, GY, Mitchel, A, et al. (1981) Effect of guar gum on blood lipids. Am J Clin Nutr 34, 24462449.CrossRefGoogle ScholarPubMed
Tuomilehto, J, Voutilainen, E, Huttunen, J, et al. (1980) Effect of guar gum on body weight and serum lipids in hypercholesterolemic females. Acta Med Scandinavica 208, 4548.CrossRefGoogle ScholarPubMed
Makkonen, M, Simpanen, AL, Saarikoski, S, et al. (1993) Endocrine and metabolic effects of guar gum in menopausal women. Gynecological Endocrinol 7, 135141.CrossRefGoogle ScholarPubMed
Wang, N, Pan, D, Guo, Z, et al. (2021) Effects of guar gum on blood lipid levels: a systematic review and meta-analysis on randomized clinical trials. J Funct Foods 85, 104605.CrossRefGoogle Scholar
Farrell, R, Owens, D & Tomkin, GH (1986) Guar in non-insulin-dependent diabetics. Pract Diabetes Int 3, 150151.CrossRefGoogle Scholar
Peterson, DB, Ellis, PR, Baylis, JM, et al. (1987) Low dose guar in a novel food product: improved metabolic control in non-insulin-dependent diabetes. Diabetic Med 4, 111115.CrossRefGoogle Scholar
Blake, DE, Hamblett, CJ, Frost, PG, et al. (1997) Wheat bread supplemented with depolymerized guar gum reduces the plasma cholesterol concentration in hypercholesterolemic human subjects. Am J Clin Nutr 65, 107113.CrossRefGoogle ScholarPubMed
Ebeling, P, Yki-Järvinen, H, Aro, A, et al. (1988) Glucose and lipid metabolism and insulin sensitivity in type 1 diabetes: the effect of guar gum. Am J Clin Nutr 48, 98103.CrossRefGoogle ScholarPubMed
Cicero, AF, Derosa, G, Manca, M, et al. (2007) Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial. Clin Exp Hypertens 29, 383394.CrossRefGoogle ScholarPubMed
Niemi, M, Keinänen-Kiukaanniemi, S & Salmela, P (1988) Long-term effects of guar gum and microcrystalline cellulose on glycaemic control and serum lipids in type 2 diabetes. Eur J Clin Pharmacol 34, 427429.CrossRefGoogle ScholarPubMed
Spiller, GA, Farquhar, JW, Gates, JE, et al. (1991) Guar gum and plasma cholesterol. Effect of guar gum and an oat fiber source on plasma lipoproteins and cholesterol in hypercholesterolemic adults. Arterioscler Thromb: J Vasc Biol 11, 12041208.CrossRefGoogle Scholar
Vaaler, S, Hanssen, K, Dahl-Jørgensen, K, et al. (1986) Diabetic control is improved by guar gum and wheat bran supplementation. Diabetic Med 3, 230233.CrossRefGoogle ScholarPubMed
Stroup, DF, Berlin, JA, Morton, SC, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283, 20082012.CrossRefGoogle ScholarPubMed
Higgins, JP, Altman, DG, Gotzsche, PC, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed) 343, d5928.CrossRefGoogle ScholarPubMed
DerSimonian, R & Laird, N (1986) Meta-analysis in clinical trials Control Clin Trials 7, 177188.CrossRefGoogle ScholarPubMed
Borenstein, M, Hedges, LV, Higgins, JP, et al. (2011) Introduction to Meta-Analysis. New York, NY: John Wiley & Sons.Google Scholar
Egger, M, Smith, GD, Schneider, M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 315, 629634.CrossRefGoogle ScholarPubMed
Mitchell, MN (2012) Interpreting and Visualizing Regression Models using STATA. vol. 558. College Station, TX: Stata Press College Station.Google Scholar
Gordon, H, Oxman, A, Vist, G, et al. (2008) Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clin Res Ed) 336, 924926.Google Scholar
Aro, A, Uusitupa, M & Voutilainen, E (1981) Long-term effects of guar gum in maturity onset diabetes. Acta Endocrinologica Supplement 98, 8.Google Scholar
Aro, A, Uusitupa, M, Voutilainen, E, et al. (1984) Effects of guar gum in male subjects with hypercholesterolemia. Am J Clin Nutr 39, 911916.CrossRefGoogle ScholarPubMed
McIvor, ME, Cummings, CC, Van Duyn, MA, et al. (1986) Long-term effects of guar gum on blood lipids. Atherosclerosis 60, 713.CrossRefGoogle ScholarPubMed
Fuessl, HS, Williams, G, Adrian, TE, et al. (1987) Guar sprinkled on food: effect on glycaemic control, plasma lipids and gut hormones in non-insulin dependent diabetic patients. Diabetic Med 4, 463468.CrossRefGoogle ScholarPubMed
Farrell, RW, Owens, D & Tomkin, GH (1986) Guar in non-insulin-dependent diabetics. Pract Diabetes Int 3, 150151.CrossRefGoogle Scholar
Uusitupa, M, Siitonen, O, Savolainen, K, et al. (1989) Metabolic and nutritional effects of long-term use of guar gum in the treatment of noninsulin-dependent diabetes of poor metabolic control. Am J Clin Nutr 49, 345351.CrossRefGoogle ScholarPubMed
Superko, HR, Haskell, WL, Sawrey-Kubicek, L, et al. (1988) Effects of solid and liquid guar gum on plasma cholesterol and triglyceride concentrations in moderate hypercholesterolemia. Am J Cardiol 62, 5155.CrossRefGoogle ScholarPubMed
Tuomilehto, J, Silvasti, M, Aro, A, et al. (1988) Long term treatment of severe hypercholesterolaemia with guar gum. Atherosclerosis 72, 157162.CrossRefGoogle ScholarPubMed
Lalor, BC, Bhatnagar, D, Winocour, PH, et al. (1990) Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabetic Med 7, 242245.CrossRefGoogle ScholarPubMed
Vuorinen-Markkola, H, Sinisalo, M & Koivisto, VA (1992) Guar gum in insulin-dependent diabetes: effects on glycemic control and serum lipoproteins. Am J Clin Nutr 56, 10561060.CrossRefGoogle ScholarPubMed
Groop, PH, Aro, A, Stenman, S, et al. (1993) Long-term effects of guar gum in subjects with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 58, 513518.CrossRefGoogle ScholarPubMed
Laajam, MA, Jim, LK, El-Bolbol, S, et al. (1990) Guar gum in non-insulin-dependent diabetes mellitus: a double-blind crossover, placebo-controlled trial in Saudi Arabian patients. Ann Saudi Med 10, 525530.CrossRefGoogle Scholar
Groop, PH, Groop, L, Tötterman, KJ, et al. (1986) Relationship between changes in GIP concentrations and changes in insulin and c-peptide concentrations after guar gum therapy. Scand J Clin Lab Invest 46, 505510.CrossRefGoogle ScholarPubMed
Trautwein, EA, Kunath-Rau, A & Erbersdobler, HF (1998) Effect of different varieties of pectin and guar gum on plasma, hepatic and biliary lipids and cholesterol gallstone formation in hamsters fed on high-cholesterol diets. Br J Nutr 79, 463471.CrossRefGoogle ScholarPubMed
Figueiredo, MD, Alfenas, RD, Franceschini, SD, et al. (2006) Effect of guar gum supplementation on lipidic and glycidic metabolic control and body mass index in type 2 diabetes. Rev Nutrição 19, 187194.CrossRefGoogle Scholar
Wirth, A, Middelhoff, G, Braeuning, C, et al. (1982) Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar. Atherosclerosis 45, 291297.CrossRefGoogle ScholarPubMed
Tuomilehto, J, Silvasti, M, Manninen, V, et al. (1989) Guar gum and gemfibrozil—an effective combination in the treatment of hypercholesterolaemia. Atherosclerosis 76, 7177.CrossRefGoogle ScholarPubMed
Gould, AL, Davies, GM, Alemao, E, et al. (2007) Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 29, 778794.CrossRefGoogle ScholarPubMed
Knopp, RH, Superko, HR, Davidson, M, et al. (1999) Long-term blood cholesterol–lowering effects of a dietary fiber supplement. Am J Prev Med 17, 1823.CrossRefGoogle ScholarPubMed
Krotkiewski, M (1984) Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. Br J Nutr 52, 97105.CrossRefGoogle ScholarPubMed
Bosello, O, Cominacini, L, Zocca, I, et al. (1984) Effects of guar gum on plasma lipoproteins and apolipoproteins C-II and C-III in patients affected by familial combined hyperlipoproteinemia. Am J Clin Nutr 40, 11651174.CrossRefGoogle ScholarPubMed
Gatti, E, Catenazzo, G, Camisasca, E, et al. (1984) Effects of guar-enriched pasta in the treatment of diabetes and hyperlipidemia. Ann Nutr Metab 28, 110.CrossRefGoogle ScholarPubMed
Burgeiro, A, Cerqueira, MG, Varela-Rodríguez, BM, et al. (2017) Glucose and lipid dysmetabolism in a rat model of prediabetes induced by a high-sucrose diet. Nutrients 9, 638.CrossRefGoogle Scholar
Yamamoto, Y, Sogawa, I, Nishina, A, et al. (2000) Improved hypolipidemic effects of xanthan gum–galactomannan mixtures in rats. Biosci Biotechnol Biochem 64, 21652171.CrossRefGoogle ScholarPubMed
Pasquier, B, Armand, M, Castelain, C, et al. (1996) Emulsification and lipolysis of triacylglycerols are altered by viscous soluble dietary fibres in acidic gastric medium in vitro . Biochem J 314, 269275.CrossRefGoogle ScholarPubMed
Zhou, J, Massey, S, Story, D, et al. (2018) Metformin: an old drug with new applications. Int J Mol Sci 19, 2863.CrossRefGoogle ScholarPubMed
Jenkins, D, Reynolds, D, Slavin, B, et al. (1980) Dietary fiber and blood lipids: treatment of hypercholesterolemia with guar crispbread. Am J Clin Nutr 33, 575581.CrossRefGoogle ScholarPubMed
Turner, P, Tuomilehto, J, Happonen, P, et al. (1990) Metabolic studies on the hypolipidaemic effect of guar gum. Atherosclerosis 81, 145150.CrossRefGoogle ScholarPubMed
Brown, L, Rosner, B, Willett, WW, et al. (1999) Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 69, 3042.CrossRefGoogle ScholarPubMed
Dikeman, CL & Fahey, GC Jr (2006) Viscosity as related to dietary fiber: a review. Crit Rev Food Sci Nutr 46, 649663.CrossRefGoogle ScholarPubMed
Rideout, TC, Harding, SV, Jones, PJ, et al. (2008) Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: current understandings and future research priorities. Vasc Health Risk Manage 4, 10231033.CrossRefGoogle ScholarPubMed
Chen, W-JL, Anderson, JW & Jennings, D (1984) Propionate may mediate the hypocholesterolemic effects of certain soluble plant fibers in cholesterol-fed rats. Proc Soc Exp Biol Med 175, 215218.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1. Flow chart of study selection for inclusion trials in the systematic review.

Figure 1

Fig. 2. Forest plot detailing weighted mean difference and 95 % CI for the effect of guar gum supplementation on: (a) TAG; (b) TC; (c) LDL-cholesterol and (d) HDL-cholesterol.

Figure 2

Fig. 3. Funnel plot for the effect of guar gum supplementation on; (a) TAG; (b) TC; (c) LDL-cholesterol and (d) HDL-cholesterol.

Figure 3

Fig. 4. Random-effects meta-regression plots of the association between dose of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Figure 4

Fig. 5. Random-effects meta-regression plots of the association between duration of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Figure 5

Fig. 6. Random-effects meta-regression plots of the association between dose of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Figure 6

Fig. 7. Random-effects meta-regression plots of the association between duration of intervention (week) and weighted mean difference of: a) TAG; b) TC; c) LDL-cholesterol and d) HDL-cholesterol.

Supplementary material: File

Setayesh et al. supplementary material

Tables S1-S4

Download Setayesh et al. supplementary material(File)
File 43.8 KB